Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,84 USD | +3,65% | -4,05% | -54,74% |
Omzet 2022 | 22,3 mln. 20,86 mln. | Omzet 2023 | 7,19 mln. 6,73 mln. | Marktkapitalisatie | 25,42 mln. 23,77 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -62 mln. -57,99 mln. | Nettowinst (verlies) 2023 | -50 mln. -46,76 mln. | EV/omzet 2022 | 2,66 x |
Nettoschuld 2022 | 48,89 mln. 45,72 mln. | Nettoschuld 2023 | 33,81 mln. 31,62 mln. | EV/omzet 2023 | 8,23 x |
K/w-verhouding 2022 |
-0,12
x | K/w-verhouding 2023 |
-0,33
x | Werknemers | 113 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 49,08% |
Recentste transcriptie over T2 Biosystems, Inc.
1 dag | +3,65% | ||
1 week | -4,05% | ||
Lopende maand | -5,33% | ||
1 maand | -6,89% | ||
3 maanden | -32,70% | ||
6 maanden | -48,27% | ||
Lopend jaar | -54,74% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Sperzel
CEO | Chief Executive Officer | 60 | 08-01-20 |
John Sprague
DFI | Director of Finance/CFO | 65 | 30-01-18 |
Roger Smith
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Elsbree
BRD | Director/Board Member | 76 | 01-07-14 |
Seymour Liebman
BRD | Director/Board Member | 74 | 21-09-16 |
Robin Toft
BRD | Director/Board Member | 63 | 14-06-20 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 2,84 | +3,65% | 140 888 |
25-04-24 | 2,74 | -0,72% | 412 422 |
24-04-24 | 2,76 | +1,47% | 330 290 |
23-04-24 | 2,72 | -13,92% | 359 187 |
22-04-24 | 3,16 | +6,76% | 1 363 736 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-54,74% | 24,97 mln. | |
+8,07% | 219 mld. | |
+6,59% | 183 mld. | |
+11,26% | 133 mld. | |
+26,57% | 108 mld. | |
+0,65% | 63,06 mld. | |
+13,35% | 52,02 mld. | |
-0,62% | 48,2 mld. | |
-0,93% | 40,37 mld. | |
+11,54% | 39,35 mld. |